GT Biologics
The company will develop and commercialise an oral-based probiotic product for the treatment of mild to moderate Crohn’s disease and ulcerative colitis and a novel family of protein/peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases.
These novel drug compounds have been derived from bacteria that naturally colonised the gut of healthy individuals and have been scientifically proven to exhibit potent anti-infectious and anti-inflammatory properties. Human gut bacteria provide a diverse and rich source of natural drugs and the company aims to use this novel platform for further drug discovery and product development.
Exploiting the intellectual property of its founder Professor Denise Kelly GT Biologics will develop new therapies for the prevention and treatment of inflammatory diseases of the human gastrointestinal tract, including Crohn’s disease and Ulcerative colitis.
Business Opportunities |
For information about business opportunities with GT-Biologics, please contact either Dr Howard Marriage or Professor Denise Kelly